NCT04262830Recruiting
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Source: ClinicalTrials.gov · Last updated 28 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 4 Nov 2019
- Start date
- 30 Sept 2019
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Hari Narayan
- Diseases
- Heart failure, Childhood cancers
- NCT number
- NCT04262830
What you commit to
- Study type: Observational
- Planned participants: 150
- From 30 Sept 2019 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
- Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
- Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
Other
- Pregnancy (at the time of enrollment).
Who the study is looking for
- English and Spanish speaking male and female subjects, ages 13-39 years old
- Diagnosis of cancer at age \<22 years
- Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
Age in the registry: 13 years to 39 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rady Children's Hospital Coordinator of this site? Confirm its status | San Diego | United States | Recruiting |
Related publications
- The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross-Sectional Study.Pediatr Blood Cancer · 2026 · PMID 42499264
This page is information, not medical advice. Discuss any trial with your doctor.